斯特赖克罕见地遭遇双倍收益失败;维持2026年指引

2026-05-01 06:17

For the first time since at least Q1 2024 results, Stryker reported misses on both the top and bottom lines in its Q1 financial results.
However, the medtech maintained its 2026 guidance: Diluted EPS of $14.90 to $15.10 (consensus $14.96). Organic sales growth is projected at 8%-9.5%.
Stryker was hurt in the quarter by just a modest increase in net sales in Q1: the $6B figure was only a 2.6% increase.
Adjusted EPS also fell year over year to $2.60 from $2.84.
Stryker ended the quarter (March 31) with cash and cash equivalents of ~$2.9B compared to ~$4B on Dec. 31, 2025.

More on Stryker